Sandoz TV Episode 18: Trailer
Find out what to expect from the newest episode of Sandoz TV.
|Global News||Sandoz Around the World||Sandoz in the Media|
Novartis delivered solid sales growth with strong margin expansion and major innovation in the third quarter
Basel, October 28, 2014
Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Novartis delivered a very strong third quarter. We delivered solid sales growth with margin expansion. At the same time, we reached key innovation milestones, particularly with LCZ696 in heart failure and AIN457 in psoriasis, underlining the innovation power of the company."
Following commitment to United Nations’ Every Newborn Action Plan, Sandoz supplies life-saving antibiotic to combat child mortality
Holzkirchen, October 23, 2014
Sandoz delivers 100,000 packs of amoxicillin 250mg dispersible tablets (DT) to UN and joins UN Pneumonia Innovations Team.
Sandoz' Mark McCamish discusses US Biosimilars landscape on Biocentury TV
October 14, 2014
Yesterday, Dr. Mark McCamish, Head Global Biopharmaceutical Development at Sandoz discussed the key issues around biosimilars in the US on "BioCentury This Week".
Sandoz wins Generics Bulletin 'Biosimilars Initiative of the Year' award
Holzkirchen, October 13, 2014
Sandoz is pleased to announce that Generics Bulletin, a newsletter covering commercial and regulatory information for the global generics industry, has awarded the company with “Biosimilars Initiative of the Year”, for its file acceptance of G-CSF (filgrastim) in the US. Sandoz also achieved top-three podium positions in the Company of the Year; Company of the Year – Americas; and Innovation of the Year Awards categories.
Sandoz receives approval in Portugal for innovative respiratory inhaler AirFluSal® Forspiro®
Holzkirchen, October 09, 2014
Sandoz announces today that the Portuguese Health Authority (Infarmed) has granted marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).